Canaccord downgraded Penumbra (PEN) to Hold from Buy with a price target of $374, up from $359. The firm cites Boston Scientific’s (BSX) agreement to acquire Penumbra in a stock-and-cash transaction that values Penumbra at $374 per share for the downgrade. Canaccord does not expect any competitive bids for Penumbra.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra: Rating Cut to Hold as Boston Scientific Takeout Caps Upside at $374 Deal Price
- Penumbra downgraded to Hold from Buy at Jefferies
- Penumbra downgraded to Hold from Buy at Needham
- Boston Scientific price target lowered to $100 from $125 at Oppenheimer
- Penumbra downgraded to Neutral from Outperform at Baird